Vogt-Koyanagi-Harada Syndrome: Clinical Features, Immunogenetic Predisposition and PD-1 Inhibitor-Induced Forms-A Comprehensive Review.

Sara Małgorzata Orłowska, Łukasz Bednarczyk, Kamal Morshed, Mateusz Tyniec, Paweł Olczyk

Abstract readReview

In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara Małgorzata OrłowskaDepartment of Health Sciences and Physical Culture, Student Scientific Association of Otolaryngology and Laryngological Oncology, Student Scientific Association "FarMedLab", Radom University, Chrobrego 27, 26-600 Radom, Poland.ORCID 0009-0008-2785-4985

Łukasz BednarczykDepartment of Health Sciences and Physical Culture, Student Scientific Association of Otolaryngology and Laryngological Oncology, Student Scientific Association "FarMedLab", Radom University, Chrobrego 27, 26-600 Radom, Poland.ORCID 0009-0002-9211-6264

Kamal MorshedClinical Department of Otolaryngology and Laryngological Oncology, Mazovian Specialist Hospital in Radom, Radom University, 5 Aleksandrowicza Street, 26-617 Radom, Poland.

Mateusz TyniecClinical Department of Otolaryngology and Laryngological Oncology, Mazovian Specialist Hospital in Radom, Radom University, 5 Aleksandrowicza Street, 26-617 Radom, Poland.

Paweł OlczykFaculty of Medical Sciences and Health Sciences, Radom University, Chrobrego 27, 26-600 Radom, Poland.ORCID 0000-0001-7387-9587

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vogt-Koyanagi-Harada syndrome (VKH) is a rare granulomatous autoimmune disease characterised by a systemic immune response directed against melanocytes. This multisystem condition primarily affects organs that are rich in melanocytes, such as the eyes, inner ear, meninges and skin. VKH might be responsible for the development of chronic uveitis and permanent visual impairment, particularly in cases where a diagnosis is delayed and treatment is not administered in a timely manner. A key factor in its pathogenesis is the loss of immune tolerance to melanocytes, driven by a T-cell-mediated immune response and genetic susceptibility, including the presence of

Indexed as

genetic predispositionimmune checkpoint inhibitorsimmune-related adverse eventimmunopathogenesisuveitisVogt-Koyanagi-Harada disease

Identifiers

PMID42123224

DOI10.3390/jcm15093490

PMCPMC13163757

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.